250
Participants
Start Date
May 27, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
Dexmedetomidine (DEX)
The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
Placebo (Saline)
The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
RECRUITING
Shanxi Cardiovascular Hospital, Taiyuan
RECRUITING
The Second Affiliated Hospital of Harbin Medical University, Harbin
RECRUITING
The First Affiliated Hospital of Anhui Medical University, Hefei
RECRUITING
Tianjin First Central Hospital, Tianjin
RECRUITING
Wuhan Asia Heart Hospital, Wuhan
RECRUITING
Henan Provincial People's Hospital, Zhengzhou
RECRUITING
Shaanxi Provincial People's Hospital, Xi'an
RECRUITING
The First Affiliated Hospital of Lanzhou University, Lanzhou
RECRUITING
Mudanjiang Cardiovascular Hospital, Mudanjiang
Yangtze River Pharmaceutical Group Co., Ltd.
INDUSTRY
Harbin Medical University
OTHER